| 7946- | BuckWS, | Extract of buckwheat sprouts scavenges oxidation and inhibits pro-inflammatory mediators in lipopolysaccharide-stimulated macrophages (RAW264.7) |
| - | Study, | Nor, | NA |
| 7945- | BuckWS, | RT, | Changes in phenols contents from buckwheat sprouts during growth stage |
| - | Study, | Nor, | NA |
| 7924- | BuckWS, | Antioxidant activity of tartary (Fagopyrum tataricum (L.) Gaertn.) and common (Fagopyrum esculentum moench) buckwheat sprouts |
| - | Review, | Nor, | NA |
| 7923- | BuckWS, | isoO, | VT, | IVT, | RT | Flavonoid analysis of buckwheat sprouts |
| - | Review, | Nor, | NA |
| 7922- | BuckWS, | isoO, | VT, | IVT, | RT | Comparison of phenolic compositions between common and tartary buckwheat (Fagopyrum) sprouts |
| - | Review, | Nor, | NA |
| 7978- | BUL, | Synthesis and Cytotoxic Property of Annonaceous Acetogenin Glycoconjugates |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 |
| 7967- | BUL, | Mode of action of bullatacin: a potent antitumor and pesticidal annonaceous acetogenin |
| - | in-vivo, | Ovarian, | A2780S | - | in-vivo, | AML, | L1210 |
| 7968- | BUL, | The Annonaceous acetogenin bullatacin is cytotoxic against multidrug-resistant human mammary adenocarcinoma cells |
| - | in-vitro, | BC, | MCF7 |
| 7969- | BUL, | Bullatacin triggered ABCB1-overexpressing cell apoptosis via the mitochondrial-dependent pathway |
| - | in-vitro, | Cerv, | KBv200 |
| 7970- | BUL, | Bullatacin triggers immunogenic cell death of colon cancer cells by activating endoplasmic reticulum chaperones |
| - | in-vitro, | Colon, | SW480 | - | in-vitro, | Colon, | HT-29 |
| 7971- | BUL, | Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe |
| - | in-vivo, | Park, | NA |
| 7972- | BUL, | Mode of action of bullatacin, a potent antitumor acetogenin: inhibition of NADH oxidase activity of HeLa and HL-60, but not liver, plasma membranes |
| - | vitro+vivo, | Cerv, | HeLa | - | vitro+vivo, | AML, | HL-60 |
| 7973- | BUL, | Bullatacin, a potent antitumor annonaceous acetogenin, inhibits proliferation of human hepatocarcinoma cell line 2.2.15 by apoptosis induction |
| - | in-vitro, | Liver, | HepG2 |
| 7974- | BUL, | Selective action of acetogenin mitochondrial complex I inhibitors |
| - | in-vitro, | Colon, | SW480 |
| 7975- | BUL, | Bullatacin--in vivo and in vitro experience in an ovarian cancer model |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 7976- | BUL, | Antitumor activity and toxicity relationship of annonaceous acetogenins |
| - | in-vitro, | HCC, | H22 |
| 7977- | BUL, | Mitochondria-mediated apoptosis induced by acetogenins from Porcelia macrocarpa (Annonaceae) in K562 chronic myeloid leukemia cells |
| - | in-vitro, | AML, | K562 |
| 5745- | Buty, | Microbial Oncotarget: Bacterial-Produced Butyrate, Chemoprevention and Warburg Effect |
| - | Review, | Var, | NA |
| 5744- | Buty, | PacT, | Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction |
| - | in-vivo, | Var, | NA |
| 5743- | Buty, | Regulation of Intestinal Butyrate Transporters by Oxidative and Inflammatory Status |
| - | Review, | Var, | NA |
| 5742- | Buty, | Butyrate: A Double-Edged Sword for Health? |
| - | Review, | Var, | NA |
| 5741- | Buty, | Rad, | Microencapsulated Sodium Butyrate in the Prevention of Acute Radiotherapy Proctitis: Single-Center Prospective Study |
| - | in-vivo, | Pca, | NA |
| 5740- | Buty, | A Review of Nutritional Regulation of Intestinal Butyrate Synthesis: Interactions Between Dietary Polysaccharides and Proteins |
| - | Review, | RCC, | NA |
| 5739- | Buty, | Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review) |
| - | Review, | Var, | NA |
| 5736- | Buty, | Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug |
| - | Trial, | Var, | NA |
| 5738- | Buty, | Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease |
| - | Review, | Nor, | NA |
| 5735- | Buty, | Butyrate and the Intestinal Epithelium: Modulation of Proliferation and Inflammation in Homeostasis and Disease |
| - | Study, | Nor, | NA |
| 5734- | Buty, | Enhanced production of IL-18 in butyrate-treated intestinal epithelium by stimulation of the proximal promoter region |
| - | vitro+vivo, | Nor, | NA |
| 5733- | Buty, | VitB3, | Activation of Gpr109a, Receptor for Niacin and the Commensal Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis |
| - | in-vivo, | CRC, | NA |
| 5732- | Buty, | GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon |
| - | Study, | CRC, | NA |
| 5731- | Buty, | The Warburg Effect Dictates the Mechanism of Butyrate Mediated Histone Acetylation and Cell Proliferation |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 |
| 5737- | Buty, | Butyrate Suppresses the Proliferation of Colorectal Cancer Cells via Targeting Pyruvate Kinase M2 and Metabolic Reprogramming |
| - | in-vitro, | CRC, | HCT116 |
| 2050- | Buty, | The Role of Sodium Phenylbutyrate in Modifying the Methylome of Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 |
| 2047- | Buty, | Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Nor, | SV-HUC-1 | - | in-vitro, | Bladder, | 5637 | - | in-vivo, | NA, | NA |
| 1224- | Buty, | Intratumor microbiome-derived butyrate promotes lung cancer metastasis |
| - | in-vivo, | Lung, | NA |
| 1080- | Buty, | Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition |
| - | in-vitro, | CRC, | HT-29 |
| 1032- | Buty, | Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer |
| - | in-vivo, | GC, | AGS |
| 1011- | CA, | Dihydrocaffeic acid improves IL-1β-induced inflammation and cartilage degradation via inhibiting NF-κB and MAPK signalling pathways |
| - | in-vivo, | Nor, | NA |
| 1101- | CA, | Tras, | Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells |
| - | in-vitro, | BC, | NA |
| 145- | CA, | CUR, | The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | PC, | DU145 |
| 7832- | CA, | CGA, | MBS, | Neuroprotective Potential of Mung Bean (Vigna radiata L.) Polyphenols in Alzheimer's Disease: A Review |
| - | Review, | AD, | NA |
| 7521- | CA, | Protective effects of caffeic acid and caffeic acid phenethyl ester against acrolein-induced neurotoxicity in HT22 mouse hippocampal cells |
| - | in-vitro, | AD, | HT22 |
| 7516- | CA, | Caffeic Acid, a Polyphenolic Micronutrient Rescues Mice Brains against Aβ-Induced Neurodegeneration and Memory Impairment |
| - | in-vivo, | AD, | NA |
| 7515- | CA, | Protective role of caffeic acid in an Aβ25-35-induced Alzheimer's disease model |
| - | in-vivo, | AD, | NA |
| 7514- | CA, | Selective toxicity of caffeic acid in hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | NA |
| 4263- | CA, | Neuroprotective Effects of Carnosic Acid: Insight into Its Mechanisms of Action |
| - | Review, | AD, | NA |
| 4265- | CA, | Potential applications of nanomedicine for treating Parkinson's disease |
| - | Review, | Park, | NA |
| 4264- | CA, | Carnosic Acid Mitigates Depression-Like Behavior in Ovariectomized Mice via Activation of Nrf2HO-1 Pathway |
| - | in-vivo, | AD, | NA |
| 4342- | CA, | Antiplatelet effects of caffeic acid due to Ca(2+) mobilizationinhibition via cAMP-dependent inositol-1, 4, 5-trisphosphate receptor phosphorylation |
| - | in-vitro, | Nor, | NA |
| 3032- | CA, | Carnosic Acid Induces Apoptosis Through Reactive Oxygen Species-mediated Endoplasmic Reticulum Stress Induction in Human Renal Carcinoma Caki Cells |
| - | in-vitro, | Kidney, | Caki-1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid